专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08852614B2 Hydrogels with network defects enhanced by nanoparticle incorporation 有权
标题翻译：通过纳米颗粒掺入增强网络缺陷的水凝胶
公开(公告)号：US08852614B2
公开(公告)日：2014-10-07
申请号：US13065030
申请日：2011-03-11
申请人： Curtis W. Frank , Won Jae Lee , Nam-Joon Cho , Jeffrey S. Glenn
发明人： Curtis W. Frank , Won Jae Lee , Nam-Joon Cho , Jeffrey S. Glenn
IPC分类号： A61K9/00 , A01N63/00 , C12N5/02 , C12N5/071 , A61K35/12 , B82Y5/00 , A61K9/51 , A61K38/00
CPC分类号： B82Y5/00 , A61K9/5184 , A61K35/12 , A61K38/00 , C12N5/0671 , C12N2533/30 , C12N2533/40 , Y10S977/773 , Y10S977/915 , Y10S977/923
摘要： Compositions and methods are provided for the manufacture and use of hydrogels with increased permeability to macromolecules with minimum loss of matrix mechanical strength and prepolymer viscosity for patternability. The hydrogels of the invention are formed from a prepolymer, which is polymerized in the presence of hydrophobic nanoparticles. In some embodiments of the invention cells are present during polymerization, and are encapsulated by the hydrogel. A high interfacial energy between the hydrophobic substrate and the aqueous polymerizing solution disrupts the hydrogel network structure, leading to network defects that increase permeability without loss of patternability.
摘要翻译：提供了组合物和方法，用于制造和使用具有增加的大分子渗透性的水凝胶，同时基质机械强度和预聚物粘度对图案性的损失最小。本发明的水凝胶由预聚物形成，预聚物在疏水性纳米颗粒存在下聚合。在本发明的一些实施方案中，细胞在聚合期间存在，并被水凝胶包封。疏水性底物和水性聚合溶液之间的高界面能量破坏了水凝胶网络结构，从而导致网络缺陷，从而增加渗透性而不损失图案性。

2. 发明申请

US20110256183A1 Hydrogels with network defects enhanced by nanoparticle incorporation 有权
标题翻译：通过纳米颗粒掺入增强网络缺陷的水凝胶
公开(公告)号：US20110256183A1
公开(公告)日：2011-10-20
申请号：US13065030
申请日：2011-03-11
申请人： Curtis W. Frank , Won Jae Lee , Nam-Joon Cho , Jeffrey S. Glenn
发明人： Curtis W. Frank , Won Jae Lee , Nam-Joon Cho , Jeffrey S. Glenn
IPC分类号： A61K9/00 , A61K35/407 , A61P1/16 , C12N5/071 , A61K35/12 , B82Y5/00
CPC分类号： B82Y5/00 , A61K9/5184 , A61K35/12 , A61K38/00 , C12N5/0671 , C12N2533/30 , C12N2533/40 , Y10S977/773 , Y10S977/915 , Y10S977/923
摘要： Compositions and methods are provided for the manufacture and use of hydrogels with increased permeability to macromolecules with minimum loss of matrix mechanical strength and prepolymer viscosity for patternability. The hydrogels of the invention are formed from a prepolymer, which is polymerized in the presence of hydrophobic nanoparticles. In some embodiments of the invention cells are present during polymerization, and are encapsulated by the hydrogel. A high interfacial energy between the hydrophobic substrate and the aqueous polymerizing solution disrupts the hydrogel network structure, leading to network defects that increase permeability without loss of patternability.
摘要翻译：提供了组合物和方法，用于制造和使用具有增加的大分子渗透性的水凝胶，同时基质机械强度和预聚物粘度对图案性的损失最小。本发明的水凝胶由预聚物形成，预聚物在疏水性纳米颗粒存在下聚合。在本发明的一些实施方案中，细胞在聚合期间存在，并被水凝胶包封。疏水性底物和水性聚合溶液之间的高界面能量破坏了水凝胶网络结构，从而导致网络缺陷，从而增加渗透性而不损失图案性。

3. 发明授权

US08211712B2 Method of fabricating lipid bilayer membranes on solid supports 失效
标题翻译：在固体支持物上制备脂质双层膜的方法
公开(公告)号：US08211712B2
公开(公告)日：2012-07-03
申请号：US11887669
申请日：2006-03-29
申请人： Nam-Joon Cho , Curtis W. Frank , Jeffrey S. Glenn , Kwang Ho Cheong
发明人： Nam-Joon Cho , Curtis W. Frank , Jeffrey S. Glenn , Kwang Ho Cheong
IPC分类号： G01N33/543
CPC分类号： G01N33/533 , B82Y5/00 , G01N33/554 , Y10T428/31678
摘要： The present invention provides a method of producing a planar lipid bilayer on a solid support. With this method, a solution of lipid vesicles is first deposited on the solid support. Next, the lipid vesicles are destabilized by adding an amphipathic peptide solution to the lipid vesicle solution. This destabilization leads to production of a planar lipid bilayer on the solid support. The present invention also provides a supported planar lipid bilayer, where the planar lipid bilayer is made of naturally occurring lipids and the solid support is made of unmodified gold or titanium oxide. Preferably, the supported planar lipid bilayer is continuous. The planar lipid bilayer may be made of any naturally occurring lipid or mixture of lipids, including, but not limited to phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinsitol, cardiolipin, cholesterol, and sphingomyelin.
摘要翻译：本发明提供了一种在固体支持物上制备平面脂双层的方法。使用该方法，首先将脂质囊泡溶液沉积在固体支持物上。接下来，通过向脂质囊泡溶液中加入两亲肽溶液使脂质囊泡不稳定。这种不稳定性导致在固体支持物上产生平面脂双层。本发明还提供了一种支撑的平面脂质双层，其中平面脂质双层由天然存在的脂质制成，并且固体支持物由未改性的金或氧化钛制成。优选地，支撑的平面脂质双层是连续的。平面脂质双层可以由任何天然存在的脂质或脂质混合物制成，包括但不限于磷脂酰胆碱，磷脂酰乙醇胺，磷脂酰丝氨酸，磷脂酰胰岛素，心磷脂，胆固醇和鞘磷脂。

4. 发明申请

US20110262565A1 PIP-2 Inhibition-Based Antiviral and Anti-Hyperlipidemic Therapies 审中-公开
标题翻译： PIP-2抑制型抗病毒和抗高脂血症治疗
公开(公告)号：US20110262565A1
公开(公告)日：2011-10-27
申请号：US12994414
申请日：2009-05-29
申请人： Jeffrey S. Glenn , Phillip S. Pang , Nam-Joon Cho , Choongho Lee
发明人： Jeffrey S. Glenn , Phillip S. Pang , Nam-Joon Cho , Choongho Lee
IPC分类号： A61K33/00 , A61K31/7036 , A61P31/12 , G01N33/53
CPC分类号： G01N33/92 , A61K31/7036 , A61K45/06 , C12Q1/18
摘要： Interaction of a specific viral domain with phosphatidylinositol 4,5-bisphosphate (PIP 2) is shown to mediate viral replication. Basic Amino Acid PIP-2 Pincer (BAAPP) domains are described herein, including, without limitation, NS5A protein of HCV, NS4B protein of HCV, poliovirus, and rhinovirus.
摘要翻译：特异性病毒结构域与磷脂酰肌醇4,5-二磷酸酯（PIP 2）的相互作用显示可介导病毒复制。本文描述了碱性氨基酸PIP-2蒎烯（BAAPP）结构域，包括但不限于HCV的NS5A蛋白，HCV的NS4B蛋白，脊髓灰质炎病毒和鼻病毒。

5. 发明申请

US20110217265A1 Screening for Inhibitors of HCV Amphipathic Helix (AH) Function 审中-公开
标题翻译：筛选HCV两性螺旋（AH）功能的抑制剂
公开(公告)号：US20110217265A1
公开(公告)日：2011-09-08
申请号：US13119245
申请日：2009-09-23
申请人： Jeffrey S. Glenn , Nam-Joon Cho , Wenjin Yang
发明人： Jeffrey S. Glenn , Nam-Joon Cho , Wenjin Yang
IPC分类号： A61K31/4965 , A61K31/497 , A61K31/7064 , A61K38/21 , A61P31/14 , C40B30/10 , C40B30/00 , G01B11/02
CPC分类号： C07K14/005 , C12N2770/24222
摘要： Screening methods are provided for identifying pharmacologic inhibitors of HCV amphipathic helix (AH) function, which inhibitors are useful in the prevention and treatment of HCV infection. Also provided are compounds useful in the inhibition of viral replication. The methods of the invention are based on the unexpected discovery that the presence of an AH, e.g. an AH of an HCV polypeptide, causes an increase in the apparent diameter of the vesicles. The methods of the invention provide for addition of AH peptides to lipid vesicles, for example in a high-throughput format; which addition may be performed in the absence or presence of a candidate pharmacologic agent. The change in apparent vesicle size is measured, and compared to control samples. An increase in vesicle size or aggregation is indicative of AH function being present; and a lack of increase is indicative that the AH function is absent or has been inhibited by a test agent.
摘要翻译：提供筛选方法用于鉴定HCV两亲性螺旋（AH）功能的药理学抑制剂，该抑制剂可用于预防和治疗HCV感染。还提供了可用于抑制病毒复制的化合物。本发明的方法基于意想不到的发现，即AH的存在，例如， HCV多肽的AH引起囊泡表观直径的增加。本发明的方法提供了将AH肽添加到脂质囊泡中，例如以高通量形式加入; 该添加可以在不存在或存在候选药理剂的情况下进行。测量明显囊泡大小的变化，并与对照样品进行比较。囊泡大小或聚集的增加表明存在AH功能; 并且缺乏增加表明AH功能不存在或已被测试者抑制。

6. 发明授权

US08895598B2 Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection 有权
标题翻译：治疗黄病毒科病毒感染的方法，用于治疗黄病毒科家族病毒感染的组合物和用于鉴定用于治疗黄病毒科家族病毒感染的组合物的筛选测定
公开(公告)号：US08895598B2
公开(公告)日：2014-11-25
申请号：US12678014
申请日：2008-09-18
申请人： Shirit Einav , Jeffrey S. Glenn , Robert McDowell , Wenjin Yang , Hadas Dvory-Sobol
发明人： Shirit Einav , Jeffrey S. Glenn , Robert McDowell , Wenjin Yang , Hadas Dvory-Sobol
IPC分类号： A61K31/415 , C07K14/005 , A61K31/67 , A61K31/7056 , A61K45/06
CPC分类号： A61K31/4184 , A61K31/67 , A61K31/7056 , A61K38/212 , A61K45/06 , C07D235/08 , C07D235/12 , C07K14/005 , C12N2770/24222 , G01N2333/186 , G01N2500/02 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395 , A61K2300/00
摘要： Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of identifying a candidate agent for the treatment of hepatitis C virus (HCV) infection, and the like.
摘要翻译：简要描述，本公开的实施方案包括组合物，药物组合物，治疗感染来自病毒的病毒的宿主的方法，鉴定用于治疗丙型肝炎病毒（HCV）感染的候选药物等的方法。

7. 发明申请

US20120148534A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION 有权
标题翻译：治疗弗氏病家族病毒感染的方法和组合
公开(公告)号：US20120148534A1
公开(公告)日：2012-06-14
申请号：US13376486
申请日：2010-03-16
申请人： Jeffrey S. Glenn , Wenjin Yang , Ingrid C. Choong
发明人： Jeffrey S. Glenn , Wenjin Yang , Ingrid C. Choong
IPC分类号： A61K38/21 , A61K31/454 , C07D403/12 , A61K31/416 , C07D231/56 , C07D413/14 , A61K31/5377 , A61K31/55 , C07D401/14 , A61K31/4439 , C07D405/14 , C07D403/14 , A61K31/506 , C07D491/08 , A61K31/7056 , A61P31/14 , C07D401/12
CPC分类号： C07K14/005 , A61K31/416 , A61K31/4439 , A61K31/454 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/7056 , A61K38/212 , A61K45/06 , C07D231/56 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D491/08 , C12N7/00 , C12N2770/24211 , C12N2770/24222 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395 , A61K2300/00
摘要： Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.
摘要翻译：简要描述，本公开的实施方案包括化合物，药物组合物，治疗感染病毒的病毒的病毒的病毒的方法，用于抑制宿主中HCV复制的方法，抑制NS4B多肽与3'端的结合的方法，宿主中HCV负链RNA的UTR，宿主中肝纤维化的治疗方法等。

8. 发明申请

US20120093849A1 Agents for Treatment of HCV and Methods of Use 有权
标题翻译： HCV治疗药物及使用方法
公开(公告)号：US20120093849A1
公开(公告)日：2012-04-19
申请号：US13326793
申请日：2011-12-15
申请人： Jeffrey S. Glenn , Tina Marie Myers , John Irvin Glass
发明人： Jeffrey S. Glenn , Tina Marie Myers , John Irvin Glass
IPC分类号： A61K39/29 , C12Q1/70 , A61P31/14 , A61K38/16 , C07K14/18 , C07H21/02
CPC分类号： C07K14/005 , A61K38/162 , A61K39/00 , C07K2319/00 , C12N2740/16322 , C12N2770/24222 , G01N33/5767 , G01N2500/02 , G01N2500/10
摘要： An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes permits identification of compounds and protocols which are useful in the treatment of HCV infection. Also useful in the invention are mimics, or function-disrupting ligands, of an amphipathic helix of the nonstructural proteins described herein and antibodies and fragments thereof immunoreactive with said helix.
摘要翻译：在丙型肝炎病毒（HCV）非结构蛋白的近似N末端的两亲螺旋介导这些蛋白质与感染细胞中细胞质膜的关联。此关联对于复制至关重要。因此，评估化合物或方案破坏这种螺旋与细胞质膜的关联的能力允许鉴定可用于治疗HCV感染的化合物和方案。在本发明中也有用的是本文所述的非结构蛋白质的两亲性螺旋的模拟物或功能性破坏性配体，以及与所述螺旋体免疫反应的抗体及其片段。

9. 发明申请

US20100260717A1 METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION 有权
标题翻译：治疗弗氏病家族病毒感染的方法，用于治疗弗氏病家族病毒感染的组合物和用于鉴定用于治疗弗氏病家族病毒感染的组合物的筛选测定
公开(公告)号：US20100260717A1
公开(公告)日：2010-10-14
申请号：US12678014
申请日：2008-09-18
申请人： Stephen R. Quake , Shirit Einav , Jeffrey S. Glenn , Robert McDowell , Wenjin Yang , Doron Gerber , Hadas Dvory-Sobol
发明人： Stephen R. Quake , Shirit Einav , Jeffrey S. Glenn , Robert McDowell , Wenjin Yang , Doron Gerber , Hadas Dvory-Sobol
IPC分类号： A61K38/21 , A61K31/4184 , A61K31/137 , A61K31/4025 , A61K31/4406 , A61K31/17 , G01N33/566 , A61P31/14
CPC分类号： A61K31/4184 , A61K31/67 , A61K31/7056 , A61K38/212 , A61K45/06 , C07D235/08 , C07D235/12 , C07K14/005 , C12N2770/24222 , G01N2333/186 , G01N2500/02 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395 , A61K2300/00
摘要： Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of identifying a candidate agent for the treatment of hepatitis C virus (HCV) infection, and the like.
摘要翻译：简要描述，本公开的实施方案包括组合物，药物组合物，治疗感染来自病毒的病毒的宿主的方法，鉴定用于治疗丙型肝炎病毒（HCV）感染的候选药物等的方法。

10. 发明申请

US20100015093A1 Methods and compositions of treating a flaviviridae family viral infection 有权
公开(公告)号：US20100015093A1
公开(公告)日：2010-01-21
申请号：US12383071
申请日：2009-03-18
申请人： Shirit Einav , Jeffrey S. Glenn , Wenjin Yang , Hadas Dvory-Sobol , Ingrid C. Choong , Robert McDowell
发明人： Shirit Einav , Jeffrey S. Glenn , Wenjin Yang , Hadas Dvory-Sobol , Ingrid C. Choong , Robert McDowell
IPC分类号： A61K38/21 , A61K31/416 , C12N5/00 , C07D231/56 , C07D401/12 , A61K31/454 , A61P31/12 , C07D403/12
CPC分类号： A61K31/416 , A61K31/426 , A61K31/4439 , A61K31/454 , A61K31/7056 , A61K38/212 , A61K45/06 , C07D231/56 , C07D401/06 , C07D401/12 , C07K14/005 , C12N2770/24122 , C12N2770/24222 , G01N2333/186 , G01N2500/02 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395 , A61K2300/00
摘要： Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式